Stocks Health care GELS
NASDAQ · Health careGelteq Ltd (GELS)
It posted a net loss of $6.6M. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on November 17, 2025.
What Gelteq Ltd does
Gelteq Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GELS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$6.6M | -$0.72 | n/a |
| 2025 | n/a | -$3.5M | -$0.44 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Gelteq Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- July 6, 2026
- June 30, 2026
- June 2, 2026
- May 26, 2026
- March 24, 2026
- December 9, 2025
- November 17, 2025
- November 3, 2025Form NT 20-F filing NT 20-F
- August 29, 2025
- July 25, 2025
Questions about GELS
What does Gelteq Ltd do?
Gelteq Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GELS.
Is Gelteq Ltd profitable?
No. In fiscal 2025 it reported a net loss of $6.6M.
When did Gelteq Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on November 17, 2025. It covers the period to June 30, 2025. Its newest filing of any kind is the foreign issuer update from July 6, 2026.
Similar companies
Compare GELS with
Follow GELS
Get an email when Gelteq Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow GELS: get an email when it filesWhere the numbers come from
Financial figures are the values Gelteq Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.